Oncology
- Preparation of an NDA, including ISS and ISE, for a drug for the treatment of acute myelogenous leukemia
- A Phase Ib open label two-arm dose finding study in patients with solid tumors
- A Phase I open label two-arm study in patients with solid tumors
- An open label Phase I dose escalation study in patients with solid tumors or lymphomas
- A Phase I dose finding study in patients with histologically or cytologically confirmed tumors or metastatic malignancies
- A Phase I study evaluating the safety, pharmacokinetics, and organ radiation dosimetry in patients with prostate cancer
- A Phase I dose escalating single-center study for acute myelogenous leukemia
- A Phase I/II study for advanced renal cell carcinoma
- A Phase I randomized, multi-center study in patients with relapsed multiple myeloma
- A Phase I randomized, multi-center study in patients with advanced solid tumors
- A Phase II randomized, single-center gene therapy study in patients with epithelial ovarian, fallopian tube or primary peritoneal carcinoma
- A Phase II randomized, multi-center study in patients with metastatic colorectal cancer
- A Phase III randomized, multi-center, open-label, parallel group study in advanced prostate cancer
- A Phase II multi-center, open-label study in ovarian cancer